Abstract:Objective To study the relationship between mutation of epidermal growth factor receptor(EGFR) gene of patients with non―small cell lung cancer(NSCLC) and origin of sample, and discuss the feasibility and reliability of tissue sample, blood sample and malignant pleural effusion sample in detection of EGFR gene mutation. Methods From July 1, 2013 to July 1, 2016, a total of 157 tissue samples, 23 blood samples and 20 malignant pleural effusion samples of NSCLCpatients from De-partment of Thoracic Surgery, Oncology and General Surgery in First Affiliated Hospital of Jinzhou Medical University were collected. The patients included 127 males and 73 females, aged 35―82 years old with mean age of 61 years old, 67 cases≤61―year―old and 133 cases > 61―year―old. The E.Z.N.A.TM Tissue DNA Kit (OMEGA company) was used to extract DNA of tissue sample, the Human EGFR Gene Mutation Fluorescence Polymerase Chain Reaction(PCR) Diagnostic Kit was used to extract the DNA of blood sample and malignant pleural effusion sample, and fluorescent quantitation RCR was used to detect the EGFR. Results The EGFR gene mutation rate of tissue samples was 42.7 %(67/157), blood samples was 34.8 % and leural effusion sample was 80.0%(16/20). The EGFR gene mutation rates of tissue samples were different in different gender(χ2=1.837, P=0.274), different age(χ2= 0.645, P = 0.247) and TNM staging(χ2= 1.645, P = 0.427), and there was no significant differ-ence between the groups . The differences in smoking and non―smoking patients were statistically significant (χ2 = 2 . 674 , P=0.036). There was no significant difference in EGFR gene mutation rates between gross and punctured samples(χ2=2.165, P = 0.374). The EGFR gene mutation rate of metastatic was higher than that of primary tumor, and the difference was statisti-cally significant(χ2=4.148, P=0.043). The EGFR gene mutation rate of adenocarcinoma was higher than that of non―adenocar-cinoma, and the difference was statistically significant(χ2=5.274, P=0.021). Conclusion The patients with adenocarcinoma showed high incidence rate of EGFR gene mutation in NSCLC patients, which is unrelated to gender, age, TNM staging, smok-ing and physical state;the EGFR mutation rate of metastatic focus is higher than that of primary focus, the patients with pleu-ral effusion have a higher EGFR mutation rate than those without pleural effusion, the patients with adenocarcinoma have higher EGFR gene mutation rate than those without adenocarcinoma. Due to the tumor heterogeneity, tumor tissues from differ-ent positions(primary and metastatic) and parts should be obtained for detection as early as possible, otherwise EGFR genetic mutation of blood sample and pleural effusion sample should be detected.

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Comparisons of EGFR Mutation Status in Tumor Tissues, Pleural Effusion Cancer Cells and Cfdna Samples of Patients with Lung Adenocarcinoma

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

The study of detection EGFR gene mutation in non-small cell lung cancer tissue and matched pleural effusion

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Comparative Study of EGFR Mutations Detected in Malignant Pleural Effusion, Plasma and Tumor Tissue in Patients with Adenocarcinoma of the Lung

Mutation of epidermal growth factor receptor gene in non-small cell lung cancer patients with different biological samples and clinical pathophysiological characteristics

Pleural Effusion As a Substitute for Tumor Tissue in Detecting EGFR/ALK Mutations in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

Clinical value of the detection of EGFR gene mutations in pleural effusion cell blocks among patients with non-small-cell lung cancer

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma.

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Comparison of Different Methods for Detecting Epidermal Growth Factor Receptor Mutations in Peripheral Blood and Tumor Tissue of Non-Small Cell Lung Cancer As A Predictor of Response to Gefitinib

[Detection of Epidermal Growth Factor Receptor Mutations in Non-Small-cell Lung Carcinoma by Direct Sequencing and Correlations with Clinicopathological Characteristics and Sample Types].

Detection Of' Epidermal Growth Factor Receptor Mutations In Plasma By Mutant-Enriched Pcr Assay For Prediction Of The Response To Gefitinib In Patients With Non-Small-Celi Lung Cancer

Value of Malignant Pleural Effusion Supernatants (mpes) in Epidermal Growth Factor Receptor (EGFR) Mutation Detection of Patients with Advanced Lung Adenocarcinoma (ADC).

Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas

Research on the gene mutation of epidermal growth factor receptor in the patients with advanced non-small cell lung cancer